Health Blog

HealthDay - (HealthDay News) -- Here are the latest clinical trials, courtesy of CenterWatch:

HealthDay - (HealthDay News) -- Here are the latest clinical trials, courtesy of CenterWatch:

Regulus Therapeutics LLC, a joint venture between Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) formed to discover, develop, and commercialize microRNA-based therapeutics, announced today the publication of new research in the journal Nature on the role of a microRNA, known as miR-21, in heart failure(1).

Today, at the 94th annual meeting of the Radiological Society of North America (RSNA) in Chicago, Royal Philips Electronics (NYSE: PHG, AEX: PHI) unveiled two innovative solutions to help radiologists save time and improve patient diagnosis.

Barts and The London NHS Trust is now fully operational following an incident last week when a computer virus infected the computer systems. The computer network has been stabilised and 97% of the Trust's 5,000 PCs have been screened and are clear of the virus. The remaining PCs, which are in non-clinical areas, will be reconnected soon.

Marshall Edwards, Inc. (NASDAQ: MSHL) today announced that it has filed an application with the United States Food and Drug Administration for an Investigative New Drug (IND) approval to undertake clinical studies with triphendiol as a chemosensitizing agent in combination with gemcitabine.

What The release of a nationwide government survey on trends and demographic use of complementary and alternative medicine (CAM) among both adults and children in the United States.

A report published today in The Journal of Bone and Joint Surgery, British Volume details four case studies where proteins used to augment bone formation in applications such as, healing of nonunion, may play a role in the development of abnormal formation of bone within extraskeletal soft tissues.

In one of the first instances of targeted drug design in psychiatric treatment, University of Pittsburgh researchers have found an experimental agent that shows promise in addressing working memory impairments that occur in the schizophrenia. The study breaks new ground in the strategy used to develop new pharmacological treatments for schizophrenia, explained David Lewis, M.D.

The Institute of Public Health (IPH) in Ireland is to launch the results of Decent Food for All (DFfA) - a major project to improve community diet - tomorrow morning, Tuesday, 2 December 2008. DFfA was funded by the Food Safety Promotion Board (safefood) and the Food Standards Agency Northern Ireland.